Enzo Biochem, Inc. v. Applera Corp.

468 F. Supp. 2d 359, 2007 U.S. Dist. LEXIS 718, 2007 WL 30338
CourtDistrict Court, D. Connecticut
DecidedJanuary 5, 2007
Docket3:04cv929 (JBA)
StatusPublished
Cited by1 cases

This text of 468 F. Supp. 2d 359 (Enzo Biochem, Inc. v. Applera Corp.) is published on Counsel Stack Legal Research, covering District Court, D. Connecticut primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Enzo Biochem, Inc. v. Applera Corp., 468 F. Supp. 2d 359, 2007 U.S. Dist. LEXIS 718, 2007 WL 30338 (D. Conn. 2007).

Opinion

RULING AND ORDER ON GENERAL ELECTRIC’S MOTION TO INTERVENE FOR LIMITED PURPOSE AND MOTION TO DISQUALIFY PLAINTIFF’S COUNSEL [DOC. #121]

ARTERTON, District Judge.

On May 23, 2006, General Electric (“GE”) moved to intervene in this action pursuant to Fed.R.Civ.P. 24 for the limited purpose of seeking to disqualify plaintiffs’ counsel, Hunton & Williams LLP (“Hun-ton”). As GE is only moving to intervene in this case for the limited purpose of filing its motion to disqualify plaintiffs counsel, and GE has a demonstrated interest in ensuring that Hunton’s representation of Enzo in this action does not compromise its attorney-client relationship with Hun-ton, the Court grants GE’s motion to intervene pursuant to Fed.R.Civ.P. 24(a) in order to consider its motion to disqualify. See, e.g., Oxford Systems, Inc. v. CellPro, Inc., 45 F.Supp.2d 1055, 1058 (W.D.Wash.1999); GATX/Airlog Co. v. Evergreen Int’l Airlines, Inc., 8 F.Supp.2d 1182, 1188 (N.D.Cal.1998).

GE claims that Hunton’s representation of Enzo in this action is directly adverse to GE in violation of Rule 1.7(a) of the Connecticut Rules of Professional Conduct. The issue before the Court is whether Hunton can represent a plaintiff in one case where the subject matter has significant overlap with that in another case in which that same plaintiff (represented by different counsel) is suing a client of Hun-ton’s. The Court concludes based on the record before it that Hunton’s disqualification is not warranted, and GE’s motion to disqualify is therefore DENIED.

I. Factual and Procedural Background

Plaintiffs Enzo Biochem, Inc. and Enzo Life Sciences, Inc. (collectively “Enzo”), and Yale University (“Yale”) filed suit against defendants Applera Corp. (“Appl-era”) and Tropix Inc. (“Tropix”) on June 7, 2004, claiming patent infringement under 35 U.S.C. §§ 271, et seq. (See Compl. [Doc. # 1] at 1.) Six patents concerning techniques and processes for the detection of nucleic acids are the subject of the case: U.S. Patent Nos. 5,476,928 (“Ward '928 Patent”), 5,449,767 (“Ward '767 Patent”), 5,328,824 (“Ward '824 Patent”), 4,711,955 (“Ward '955 Patent”), 5,082,830 (“Brakel Patent”), and 4,994,373 (“Stavrianopoulos Patent”). (See id. at 1-2.) The Court issued its Claim Construction Ruling on the disputed claims and terms of these patents on October 13, 2006. (See [Doe. # 137].)

On July 17, 2006, a claim construction ruling covering some of the same terms and claims of these patents was issued in Enzo Biochem, Inc., et al. v. Amersham PLC, et al., 439 F.Supp.2d 309 (S.D.N.Y.2006). Due to some divergent constructions by the two courts, this Court certified Applera for interlocutory appeal to *361 the Federal- Circuit pursuant to 28 U.S.C. 1292(b) [Doc. # 137], The Federal Circuit denied both Enzo’s and Applera’s petitions for permission to bring this interlocutory appeal on November 27, 2006.

The Amersham action was commenced on October 23, 2002 (GE Mot. [Doc. # 121] at 2-3). In October 2003, GE announced its acquisition of Amersham, which was finalized April 8, 2004. (See GE Mot. at 3.) Also in October 2003, Enzo retained Hunton to prepare the Applera action, which was filed in June 2004. 1 (See Fedus Aff., Pis. Ex. 6, ¶ 3.) Enzo retained Green-berg Traurig LLP (“Greenberg”) in the Amersham action in mid-2004. (See Fe-dus Aff., Pis. Ex. 6 [Doc. #127-16], ¶2.)

According to GE, it is “a long-standing client” of Hunton’s — the division GE Healthcare has been a client of Hunton’s since November 14, 2001 (Schulman Aff., Pis. Ex. 3 [Doc. # 127-5], ¶ 3) — and Hun-ton “continues to represent GE on various matters, including intellectual property matters.” (GE Mot. at 3.)

In July 2005, Hunton associates Jeffrey Perez and David Kelly, and Hunton partner Scott Robertson attended the Markman hearing in Amersham. (See Pls. Opp. Mem. [Doc. # 127-2] at 7; Robertson Aff., Pis. Ex. 7 [Doc. # 127-17], ¶ 10.) On August 4, 2005, at a deposition of inventor Dr. David C. Ward in Amersham, Hunton lawyer Jeffrey Perez was in attendance and “appeared” “for Biochem, Inc.” (Ward Dep. Tr„ GE Ex. I-A [Doc. # 121-2], at 579.) At the deposition, Amersham’s counsel Jennifer A. Sklenar engaged in the following colloquy with Greenberg attorney Scott J. Bornstein and Yale’s attorney Levina Wong after the witness was questioned about a conversation he had with Hunton attorney Perez regarding distribution agreements:

Q (Mr. Ulmer, counsel for defendant Affymetrix). In the preparation session that you had for this deposition that Mr. Perez attended, did'he say anything at the — in that session?
A (Mr. Ward). No. Mr. Bornstein was the one who did the majority of the talking, ...
Q. But Mr. Perez did speak, right?
A. Yes.
Q. Do you recall anything that Mr. Perez said?
Mr. Bornstein: You can answer that yes or no.
The Witness: Yes.
Q. (By Mr. Ulmer) What was that?
Mr. Bornstein: (speaking to the witness) I’m going to direct you not to answer on the basis of the attorney-client privilege.
Ms. Sklenar: Just so we have it clear on the record, are you taking the position that for conversations that Hunton & Williams participates in that there is a privilege?
Ms. Wong: Yes.
Mr Bornstein: ’ I’m happy to tell you, as you know, that Hunton & Williams represents Enzo in connection with litigation.
Ms. Wong: Hunton & Williams also represents Yale in connection with the Enzo litigation.

(Id. at 679-81.)

Based on Perez’s appearance at that deposition, chief litigation counsel of GE *362 Healthcare, Patrick Murphy, avers that he “immediately complained to Huntoris litigation chairman, Thomas Slater” by phone and email in July and August 2005. (Murphy Aff., GE Ex. II [Doc. # 121-3], ¶ 6.) According to Murphy, “Slater assured me that this cross-over had been inadvertent and that Hunton would not participate in activities adverse to GE. Specifically, Hun-ton promised to maintain an ethical wall between the Connecticut action and the New York action.” (Id.) Slater states that,

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Ardemasov v. Citibank, N.A.
14 F. Supp. 3d 39 (D. Connecticut, 2014)

Cite This Page — Counsel Stack

Bluebook (online)
468 F. Supp. 2d 359, 2007 U.S. Dist. LEXIS 718, 2007 WL 30338, Counsel Stack Legal Research, https://law.counselstack.com/opinion/enzo-biochem-inc-v-applera-corp-ctd-2007.